XM không cung cấp dịch vụ cho cư dân của Mỹ.
F
F

FreseniusMedical


Tin tức

Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site

BUZZ-Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts Roche ROG.S to "sell" from "buy", citing limited catalyst due to a risk of Roche creating a lot of sunk cost for little ultimate return ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an
A
B
F
J
R
R
S
P
F

'Medicine is starting to work', JPM upgrades Fresenius

BUZZ-'Medicine is starting to work', JPM upgrades Fresenius ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an end ** The broker says Fresenius delivered results above expectations in each of the last four quarters and management made progress in improv
F
F

Banco, Shell, WH Smith

EUROPE RESEARCH ROUNDUP-Banco, Shell, WH Smith Sept 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Banco, Shell and WH Smith on Thursday. HIGHLIGHTS * ABN Amro Bank NV ABNd.AS : JP Morgan raises to neutral from underweight * Banco Bpm BAMI.MI : JP Morgan raises to neutral from underweight * Shell Plc SHEL.L : Berenberg cuts target price to 3,100p from 3,400p * UMG UMG.AS : Citigroup cuts target price to EUR 26 from EUR 29.50 *
A
B
B
B
C
C
C
C
D
D
D
D
E
E
E
E
I
I
I
N
O
P
R
R
R
S
S
W
P
A
B
B
F
L
U

Nestle replaces CEO Schneider with company veteran Freixe

UPDATE 6-Nestle replaces CEO Schneider with company veteran Freixe Adds Freixe's age and background in paragraph 15, and further comment, no other changes By John Revill and Richa Naidu ZURICH/LONDON, Aug 22 (Reuters) - Nestle NESN.S is replacing CEO Mark Schneider with company veteran Laurent Freixe, the Swiss food group said on Thursday, marking a change of leadership as it faces a challenge to grow sales.
D
N
F

Bodycote, Croda, Spectris

EUROPE RESEARCH ROUNDUP- Bodycote, Croda, Spectris July 31 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bodycote, Croda and Spectris, on Wednesday. HIGHLIGHTS * Bodycote Plc BOY.L : HSBC cuts target price to 940p from 950p * Bucher Industries AG BUCN.S : Berenberg cuts target price to CHF 464 from CHF 470 * Croda CRDA.L : HSBC cuts target price to 4400p from 4800p * Spectris Plc SXS.L : JP Morgan raises target price to 2,950p fr
A
A
A
B
B
B
C
C
C
C
D
D
E
E
G
G
H
I
L
S
S
S
A
D
F
I
I
P

Fresenius beats Q2 view on strong unit performance, cost savings

UPDATE 2-Fresenius beats Q2 view on strong unit performance, cost savings Adds details on restructuring in paragraphs 5, 6, profit for units in paragraph 7 By Bartosz Dabrowski July 31 (Reuters) - German healthcare group Fresenius FREG.DE beat second-quarter operating profit expectations on Wednesday, citing strong performance at its Kabi and Helios units, and progress in group-wide cost savings.
F
F

Fresenius beats Q2 expectations on strong unit performance, cost savings

Fresenius beats Q2 expectations on strong unit performance, cost savings July 31 (Reuters) - German healthcare group Fresenius FREG.DE beat second-quarter operating profit expectations on Wednesday, citing strong performance at its Kabi and Helios units, and progress in group-wide cost savings. It reported earnings before interests and taxes (EBIT) of 660 million euros ($714 million), up 16% from a year ago.
F
F

Fresenius Medical Care AG reports results for the quarter ended in June - Earnings Summary

Fresenius Medical Care AG reports results for the quarter ended in June - Earnings Summary Fresenius Medical Care AG FMEG.DE reported quarterly adjusted earnings of 48 cents​​ per share for the quarter ended in June, lower than the same quarter last year, when the company reported EPS of 60 cents. The mean expectation of six analysts for the quarter was for earnings of 67 cents per share.
F

FMC hits 5-month low after it cuts outlook for US volume growth

BUZZ-FMC hits 5-month low after it cuts outlook for US volume growth ** Shares in Fresenius Medical Care FMEG.DE fall as much as 9% to a five-month low after it cut 2024 outlook for volumes in its key U.S. market ** The world's largest dialysis specialist sees flat to 0.5% treatment volume growth in the U.S., down from the previously expected 0.5%
B
F

Dialysis firm FMC cuts outlook for US treatment volumes, shares fall

UPDATE 1-Dialysis firm FMC cuts outlook for US treatment volumes, shares fall Recasts with US patient volumes outlook, adds shares in paragraph 4 July 30 (Reuters) - World's largest dialysis specialist Fresenius Medical Care FMEG.DE cut the outlook for volumes in its key U.S. market on Tuesday after revenue from treatments there fell in the second quarter, weighed down by elevated mortality due to COVID-19 and flu among its patients.
F
F

Dialysis specialist FMC's Q2 profit meets expectations

Dialysis specialist FMC's Q2 profit meets expectations July 30 (Reuters) - World's largest dialysis specialist Fresenius Medical Care FMEG.DE reported adjusted second-quarter operating profit in line with expectations on Tuesday. Robust earnings in its health care products division, which produces dialysis machines, helped offset weaker patient volumes in the main health care services division, which provides dialysis procedures.
F
F

Fresenius Medical Care AG <FMEG.DE> expected to post earnings of 67 cents a share - Earnings Preview

Fresenius Medical Care AG expected to post earnings of 67 cents a share - Earnings Preview Fresenius Medical Care AG FMEG.DE is expected to show a rise in quarterly revenue when it reports results on July 30 for the period ending June 30 2024 The Bad Homburg Vor Der Hohe Hessen-based company is expected to report a 2.9% increase in revenue to €4.964 billion from €4.83 billion a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
F

Fresenius Medical Care AG <FMS.N> expected to post earnings of 34 cents a share - Earnings Preview

Fresenius Medical Care AG expected to post earnings of 34 cents a share - Earnings Preview Fresenius Medical Care AG FMS.N , FMS is expected to show a fall in quarterly revenue when it reports results on July 30 for the period ending June 30 2024 The Bad Homburg Vor Der Hohe Hessen-based company is expected to report a 0.3% decrease in revenue to €4.812 billion from €4.83 billion a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
F

MS raises Fresenius to 'overweight' on 'tipping point on portfolio simplification'

BUZZ-MS raises Fresenius to 'overweight' on 'tipping point on portfolio simplification' ** Morgan Stanley raises Fresenius FREG.DE to "overweight" from "equal weight," as it sees the German healthcare group has "reached a tipping point on portfolio simplification" ** The analyst says that Kabi, the company's division for IV drugs, nutrition product
F
F

DaVita falls on reaching agreement with US DOJ to resolve illegal kickback allegations

BUZZ-DaVita falls on reaching agreement with US DOJ to resolve illegal kickback allegations ** Shares of healthcare company DaVita DVA.N fall 2.8% to $135.93 in afternoon trade ** Co mpany says it has agreed to pay over $34 mln to the U.S. Department of Justice (DOJ) for resolving allegations of paying illegal kickbacks to nephrologists and vascular access physicians to induce referral of patients to its dialysis centers ** DOJ alleges DaVita paid "improper remuneration" to a large nephrology pr
F
D

DaVita falls on report of FTC launching an investigation into co

BUZZ-DaVita falls on report of FTC launching an investigation into co ** Shares of dialysis firm DaVita DVA.N fall 2.8% to $137.59 ** The U.S. Federal Trade Commission is investigating DVA and Fresenius Medical Carev FMEG.DE over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday ** The F
F
D

US FTC probing DaVita, Fresenius Medical, Politico reports

UPDATE 1-US FTC probing DaVita, Fresenius Medical, Politico reports Adds more details in paragraph 4, background in paragraph 6 July 13 (Reuters) - The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita DVA.N and Fresenius Medical Care FMEG.DE over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.
F
D

US Federal Trade Commission Is Investigating Dialysis Providers Davita And Fresenius Medical Care- Politico

BRIEF-US Federal Trade Commission Is Investigating Dialysis Providers Davita And Fresenius Medical Care- Politico July 13 (Reuters) - US FEDERAL TRADE COMMISSION IS INVESTIGATING DIALYSIS PROVIDERS DAVITA AND FRESENIUS MEDICAL CARE- POLITICO Source https://tinyurl.com/ym3t3yby
F
D

US FTC probing DaVita, Fresenius Medical, Politico reports

US FTC probing DaVita, Fresenius Medical, Politico reports July 13 (Reuters) - The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita DVA.N and Fresenius Medical Care FMEG.DE over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.
F
D



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.